ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group
 

LOGIN



Please enter your username and password.


Username

Password


  
ANZMTG
 

Closed Trials

ANZMTG 01.02 - Adjuvant Radiotherapy Trial

The use of radiotherapy after therapeutic lymphadenectomy for patients with melanoma at high risk of further lymph-node field and distant recurrence is controversial.

This is the first completed study to assess the effects of RT on regional recurrence, survival, morbidity and quality of life (QOL) in these patients.

Click here for more information

ANZMTG 01.07 - WBRTMel Trial

This international, randomized, phase III trial will determine if the addition of whole brain radiotherapy after surgery or local stereotactic radiotherapy improves the control of melanoma metastases in the brain, neurocognitive function, survival and quality of life.

Click here for more information

ANZMTG 02.09 Mel-D Trial - Vitamin D following primary treatment of melanoma at high risk of recurrence

There is currently no high evidence to show that Vitamin D can improve melanoma prognosis. This is a pilot phase II study which aims to  determine whether administration of a loading oral dose of 500,000 IU of Vitamin D followed by a monthly oral dose of 50,000 IU of Vitamin D for 2 years following primary treatment of melanoma at high risk of recurrence.

Click here for more information

ANZMTG - MSLT II

A phase III multicenter randomised trial of sentinel lymphadenectomy and complete lymph node dissection versus sentinel lyphadenectomy alone, in cutaneous melanoma patients with molecular or histopathological evidence of metastases in the sentinel node (MSLT II).

Click here for more information

Return to Trials main page.